Yeşim SÜCÜLLÜ KARADAĞ, Tankut KÖSEOĞLU, Emin ALTIPARMAK, Ömer ÖZTÜRK, Tuğçe SALTOĞLU, Fadime ERDOĞAN KÜÇÜKDAĞLI

Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients

Background/aim: Levodopa-carbidopa intestinal gel (LCIG) is an effective treatment modality in the management of advanced Parkinson’s disease (PD) despite frequent adverse events and different rates of dropouts. Efficacy and safety data regarding Turkish patients on LCIG are limited. This study aims to report in detail the efficacy and adverse effect profile of LCIG among advanced PD patients from a Turkish center for movement disorders. Materials and methods: Twenty-two patients (50% male) who started receiving LCIG between December 2014 and March 2020 were recruited. The efficacy of LCIG was assessed with the Unified Parkinson’s Disease Rating Scale (UPDRS III), Clinical Global İmprovement (CGI) scale, and Quality of Life scale (PDQ8). Improvements in gait disorders and nonmotor features were also questioned. Adverse events (AE) were collated into 3 topics: related to percutaneous endoscopic gastrojejunostomy (PEG-J), device-related, and LCIG infusion-related. Results: Mean age and pre-LCIG disease duration were 66.7 (8.8) and 13.3 (8.0) years respectively. UPDRS III scores and H-Y scale assessments significantly improved. Better quality of life scores, clinical global improvements, and improvements in dysarthria, dysphagia, and gait were observed. None of our patients dropped out or died during a mean 17.5-month (12.3) period. Overall 20 (90.9%) patients experienced at least one AE. Twelve patients had PEG-J–related complications; three had acute abdomen. Eight (36.4%) patients had device-associated problems. Half of the patients required at least one additional endoscopic procedure and 7 had a device replaced. Mean body weight decreased from 69.5 to 62.5 kg and seven patients had newly onset PNP at a follow-up electromyography. Dyskinesia related to LCIG infusion was observed in 5 (22.7%) patients. There was no significant increase in hallucination among patients. Conclusion: LCIG is an efficient treatment modality in the management of Turkish patients with advanced Parkinson’s disease. Although most of the patients had at least one AE, none of them dropped out. Patient selection, patient compliance, and collaborative management are important steps affecting the success of modality.Key words: Advanced Parkinson’s disease, LCIG, Duodopa, PEG-J, dyskinesia, PDQ

PDF

___

1. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain 2000; 123: 2297-2305. doi: 10.1093/brain/123.11.2297
2. Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernäs H et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clinical Neuropharmacology 2003; 26: 156-163. doi: 10.1097/00002826-200305000-00010
3. Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64: 216-223. doi: 10.1212/01.WNL.0000149637.70961.4C
4. Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B et al. GLORIA study co-investigators. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: Final results of the GLORIA registry. Parkinsonism & Related Disorders 2017; 45: 13-20. doi: 10.1016/j.parkreldis.2017.09.018
5. Buongiorno M, Antonelli F, Cámara A, Puente V, de FabreguesNebot O et al. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. Parkinsonism & Related Disorders 2015; 21: 871-876. doi: 10.1016/j. parkreldis.2015.05.014
6. Rispoli V, Simioni V, Capone JG, Golfrè Andreasi N, Preda F et al. Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation. Acta Neurologica Scandinavica 2017; 136: 660-667. doi: 10.1111/ane.12783
7. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. Journal of Neurology, Neurosurgery & Psychiatry 1992; 184: 181-184. doi: 10.1136/ jnnp.55.3.181
8. Devos D; French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Movement Disorders 2009; 24: 993-1000. doi: 10.1002/mds.22450
9. Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S et al. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year experience. European Journal of Neurology 2014; 21: 312-318. doi: 10.1111/ene.12309
10. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Movement Disorders 2009; 24: 1468-1474. doi: 10.1002/mds.22596
11. Cáceres-Redondo MT, Carrillo F, Lama MJ, HuertasFernández I, Vargas-González L et al. Long-term levodopa/ carbidopa intestinal gel in advanced Parkinson’s disease. Journal of Neurology 2014; 261: 561-569. doi: 10.1007/s00415- 013-7235-1
12. Romagnolo A, Merola A, Artusi CA, Rizzone MG, Zibetti M et al. Levodopa-Induced Neuropathy: A Systematic Review. Movement Disorders Clinical Practice 2018; 62: 96-103. doi: 10.1002/mdc3.12688
13. Rispoli V, Simioni V, Capone JG, Golfrè Andreasi N, Preda F et al. Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation. Acta Neurologica Scandinavica 2017; 136: 660-667. doi: 10.1111/ane.12783
14. Toth C, Breithaupt K, Ge S, Duan Y, Terris JM et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Annals of Neurology 2010; 68: 28-36. doi: 10.1002/ ana.22021